OPKO Health Announces Dosing of First Patient in Phase 2a Clinical Study of a Long-Acting Factor VIIa for the Treatment of Hemophilia
February 23, 2016 at 08:33 AM EST
OPKO Health, Inc. (NYSE: OPK) today announced dosing of the first patient in a Phase 2a study evaluating the safety of a long-acting ...